tiprankstipranks
Advertisement
Advertisement

KYTX Stock Latest News

Kyverna Therapeutics Names Gregory Martini as New CFO
Company AnnouncementsKyverna Therapeutics Names Gregory Martini as New CFO
3d ago
8K
KYTX
Kyverna Therapeutics CFO Marc Grasso to step down, Greg Martini to succeed
PremiumThe Fly
Kyverna Therapeutics CFO Marc Grasso to step down, Greg Martini to succeed
3d ago
IRWD
KYTX
Kyverna Therapeutics price target raised to $25 from $20 at H.C. Wainwright
PremiumThe Fly
Kyverna Therapeutics price target raised to $25 from $20 at H.C. Wainwright
6d ago
KYTX
Kyverna Therapeutics price target lowered to $29 from $30 at JPMorgan
PremiumThe Fly
Kyverna Therapeutics price target lowered to $29 from $30 at JPMorgan
8d ago
KYTX
Kyverna Therapeutics reports Q1 EPS (66c), consensus (73c)
PremiumThe Fly
Kyverna Therapeutics reports Q1 EPS (66c), consensus (73c)
9d ago
KYTX
Kyverna Therapeutics appoints Nadia Dac as chief commercial officer
PremiumThe FlyKyverna Therapeutics appoints Nadia Dac as chief commercial officer
17d ago
KYTX
OMER
Kyverna Therapeutics Appoints Chief Commercial Officer for Growth
Premium
Company Announcements
Kyverna Therapeutics Appoints Chief Commercial Officer for Growth
17d ago
8K
KYTX
3 High-Risk, High-Reward Stocks to Buy Now for Explosive Upside, According to Analysts – 4/23/2026
Premium
Market News
3 High-Risk, High-Reward Stocks to Buy Now for Explosive Upside, According to Analysts – 4/23/2026
28d ago
ALT
BTBT
Kyverna Therapeutics: Strong CAR‑T Efficacy and Safety in SPS and gMG Underpin Buy Rating and $20 Target
PremiumRatings
Kyverna Therapeutics: Strong CAR‑T Efficacy and Safety in SPS and gMG Underpin Buy Rating and $20 Target
28d ago
KYTX
Kyverna announces strong Phase 2/3 CAR T neuroimmunology data
PremiumCompany Announcements
Kyverna announces strong Phase 2/3 CAR T neuroimmunology data
29d ago
8K
KYTX
Kyverna Reports Positive Phase 2 Data in Stiff Person Syndrome
PremiumCompany Announcements
Kyverna Reports Positive Phase 2 Data in Stiff Person Syndrome
29d ago
8K
KYTX
Kyverna Therapeutics reports ‘positive’ results from KYSA-8 trial of miv-cel
PremiumThe Fly
Kyverna Therapeutics reports ‘positive’ results from KYSA-8 trial of miv-cel
30d ago
KYTX
Kyverna Therapeutics: Strengthened Buy Rating on Robust Miv-cel Data and Reduced Regulatory Risk in gMG
PremiumRatingsKyverna Therapeutics: Strengthened Buy Rating on Robust Miv-cel Data and Reduced Regulatory Risk in gMG
1M ago
KYTX
Kyverna Therapeutics presents longer-term Phase 2 data for Miv-cel
Premium
The Fly
Kyverna Therapeutics presents longer-term Phase 2 data for Miv-cel
1M ago
KYTX
Kyverna Reports Positive Phase 2 Data in Myasthenia Gravis
Premium
Company Announcements
Kyverna Reports Positive Phase 2 Data in Myasthenia Gravis
1M ago
8K
KYTX
Kyverna Therapeutics files $300M mixed securities shelf
PremiumThe Fly
Kyverna Therapeutics files $300M mixed securities shelf
2M ago
KYTX
Kyverna Therapeutics reports Q4 EPS (80c), consensus (86c)
PremiumThe Fly
Kyverna Therapeutics reports Q4 EPS (80c), consensus (86c)
2M ago
KYTX
Kyverna Therapeutics Strengthens Board With New Director Appointments
PremiumCompany Announcements
Kyverna Therapeutics Strengthens Board With New Director Appointments
3M ago
8K
KYTX
Kyverna Therapeutics appoints Sravan Emany, Andrew Miller to board
PremiumThe Fly
Kyverna Therapeutics appoints Sravan Emany, Andrew Miller to board
3M ago
BEAM
KYTX
Kyverna Therapeutics Appoints New CTO to Drive CAR-T Manufacturing
PremiumCompany AnnouncementsKyverna Therapeutics Appoints New CTO to Drive CAR-T Manufacturing
4M ago
8K
KYTX
Kyverna Therapeutics appoints Pujols as Chief Technology Officer
Premium
The Fly
Kyverna Therapeutics appoints Pujols as Chief Technology Officer
4M ago
KYTX
Kyverna Therapeutics: Strong Early Autoimmune CAR-T Data, Accelerated SPS Timeline, and Solid Cash Runway Support Buy Rating
Premium
Ratings
Kyverna Therapeutics: Strong Early Autoimmune CAR-T Data, Accelerated SPS Timeline, and Solid Cash Runway Support Buy Rating
4M ago
KYTX

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >